Poster on Cyclosert Drug Delivery Presented at AACR Meeting
Novel System May Provide Cancer Patients With Improved Potential to
Battle Their Disease
PASADENA, Calif., April 16, 2007 /PRNewswire/ -- Insert
Therapeutics, Inc., a majority-owned subsidiary of Arrowhead
Research Corporation announced today its novel delivery system
called Cyclosert(TM) will be ...
Arrowhead Subsidiaries Insert & Calando Present Data on
Cyclosert Drug Delivery System at AACR Meeting
... treatment of cancer using our
is the first nanoparticle drug transport platform ...peating molecules of glucose called
promotes the ability of cytotoxic drugs to
present data from animal studies using the cyclosert
augmented by Calando's own proprietary tech...
Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from
Human Clinical Trials for New Cancer Drug
...ies later this year or early next year.
"It is gratifying to see that the cyclosert
system is working as
designed in patients," said Dr. Mark Davis, inventor o...alize
drug-delivery-enhanced small-molecule therapeutics and nucleic
uses cyclodextrins as building blocks to create an
entirely new class of bi...